Cargando…
Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV
BACKGROUND: Hepatitis B virus (HBV) vaccine seroprotection rates with conventional aluminum adjuvanted recombinant HBV vaccines, Engerix-B (HepB-alum) vaccine, among people with HIV (PWH) are varied. Heplisav-B (HepB-CpG) vaccine, a novel adjuvanted recombinant HBV vaccine, has shown higher seroprot...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300634/ https://www.ncbi.nlm.nih.gov/pubmed/37389224 http://dx.doi.org/10.1093/ofid/ofad267 |
_version_ | 1785064627559727104 |
---|---|
author | Reilly-Evans, Brenna Dudzik, Beatrix Costlow, David J Hartmann, Carlos Khalsa, Ann M Kassis, Christelle Zmarlicka, Monika T |
author_facet | Reilly-Evans, Brenna Dudzik, Beatrix Costlow, David J Hartmann, Carlos Khalsa, Ann M Kassis, Christelle Zmarlicka, Monika T |
author_sort | Reilly-Evans, Brenna |
collection | PubMed |
description | BACKGROUND: Hepatitis B virus (HBV) vaccine seroprotection rates with conventional aluminum adjuvanted recombinant HBV vaccines, Engerix-B (HepB-alum) vaccine, among people with HIV (PWH) are varied. Heplisav-B (HepB-CpG) vaccine, a novel adjuvanted recombinant HBV vaccine, has shown higher seroprotection rates in immunocompetent patients but is not well studied in PWH. There are no published studies comparing seroprotection rates between HepB-alum and HepB-CpG in PWH. This study aims to evaluate and compare the seroprotection incidence of HepB-alum vs HepB-CpG in PWH at least 18 years of age. METHODS: This retrospective, observational cohort study included adults diagnosed with HIV who received a complete series of HepB-alum or HepB-CpG at a community health center in Phoenix, Arizona. Patients had a hepatitis B surface antibody <10 IU/L at the time of the first vaccine dose. The primary outcome was a comparison of seroconversion incidence between HepB-CpG and HepB-alum. Secondary outcomes included identifying factors associated with likelihood of response to HBV vaccination. RESULTS: A total of 120 patients were included in this study, 59 in the HepB-alum cohort and 61 in the HepB-CpG cohort. In the HepB-alum cohort, 57.6% achieved seroconversion, compared with 93.4% in the HepB-CpG cohort (P < .001). Those without diabetes were more likely to have response to a vaccine. CONCLUSIONS: Among PWH at a single community health center, HepB-CpG provided a statistically higher incidence of seroprotection against HBV compared with HepB-alum. |
format | Online Article Text |
id | pubmed-10300634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103006342023-06-29 Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV Reilly-Evans, Brenna Dudzik, Beatrix Costlow, David J Hartmann, Carlos Khalsa, Ann M Kassis, Christelle Zmarlicka, Monika T Open Forum Infect Dis Major Article BACKGROUND: Hepatitis B virus (HBV) vaccine seroprotection rates with conventional aluminum adjuvanted recombinant HBV vaccines, Engerix-B (HepB-alum) vaccine, among people with HIV (PWH) are varied. Heplisav-B (HepB-CpG) vaccine, a novel adjuvanted recombinant HBV vaccine, has shown higher seroprotection rates in immunocompetent patients but is not well studied in PWH. There are no published studies comparing seroprotection rates between HepB-alum and HepB-CpG in PWH. This study aims to evaluate and compare the seroprotection incidence of HepB-alum vs HepB-CpG in PWH at least 18 years of age. METHODS: This retrospective, observational cohort study included adults diagnosed with HIV who received a complete series of HepB-alum or HepB-CpG at a community health center in Phoenix, Arizona. Patients had a hepatitis B surface antibody <10 IU/L at the time of the first vaccine dose. The primary outcome was a comparison of seroconversion incidence between HepB-CpG and HepB-alum. Secondary outcomes included identifying factors associated with likelihood of response to HBV vaccination. RESULTS: A total of 120 patients were included in this study, 59 in the HepB-alum cohort and 61 in the HepB-CpG cohort. In the HepB-alum cohort, 57.6% achieved seroconversion, compared with 93.4% in the HepB-CpG cohort (P < .001). Those without diabetes were more likely to have response to a vaccine. CONCLUSIONS: Among PWH at a single community health center, HepB-CpG provided a statistically higher incidence of seroprotection against HBV compared with HepB-alum. Oxford University Press 2023-05-17 /pmc/articles/PMC10300634/ /pubmed/37389224 http://dx.doi.org/10.1093/ofid/ofad267 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Reilly-Evans, Brenna Dudzik, Beatrix Costlow, David J Hartmann, Carlos Khalsa, Ann M Kassis, Christelle Zmarlicka, Monika T Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title | Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title_full | Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title_fullStr | Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title_full_unstemmed | Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title_short | Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV |
title_sort | observational study evaluating the seroprotection of hepb-alum vaccine and hepb-cpg vaccine in people with hiv |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300634/ https://www.ncbi.nlm.nih.gov/pubmed/37389224 http://dx.doi.org/10.1093/ofid/ofad267 |
work_keys_str_mv | AT reillyevansbrenna observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT dudzikbeatrix observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT costlowdavidj observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT hartmanncarlos observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT khalsaannm observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT kassischristelle observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv AT zmarlickamonikat observationalstudyevaluatingtheseroprotectionofhepbalumvaccineandhepbcpgvaccineinpeoplewithhiv |